Recurrent Non-small Cell Lung Cancer Completed Phase 2 Trials for Cetuximab (DB00002)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00118183Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerTreatment
NCT00368992S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung CancerTreatment
NCT00986674Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung CancerTreatment